文献速递瓣膜病与结构性心脏病

抗凝治疗对经导管主动脉瓣置换术后瓣膜血流动力学退变的影响

Impact of anticoagulation therapy on valve haemodynamic deterioration following transcatheter aortic valve replacement.
PubMed 文献 · Heart · 2018-02-13

这项多中心研究纳入2466例TAVR术后患者,根据是否使用抗凝治疗分组,并经倾向评分匹配分析。结果显示非抗凝组随访时跨瓣平均压差显著升高,瓣膜血流动力学退变(VHD)发生率显著高于抗凝组(0.6% vs 3.7%,P<0.001),但VHD多无症状且未增加死亡或卒中风险。

要点

  • TAVR术后未抗凝与跨瓣压差升高及VHD风险增加相关。
  • 抗凝组VHD发生率0.6%,非抗凝组3.7%,匹配后差异仍显著。
  • VHD多为亚临床,未与全因死亡、心血管死亡或卒中风险增加相关。

核心结论

  • TAVR术后缺乏抗凝治疗与跨瓣压差显著升高及VHD风险增加相关。
  • VHD多数为亚临床,未与主要不良临床事件相关。

研究设计与样本

  • 多中心研究纳入2466例TAVR术后患者(46%男性,平均年龄81±7岁),均于12个月随访时行超声心动图。
  • 抗凝治疗组707例(28.7%),其中663例使用维生素K拮抗剂,44例使用直接口服抗凝药。
  • 采用倾向评分匹配分析,每组622例。
  • VHD定义为随访时(对比出院时)平均跨假体压差较出院时增加≥10 mm Hg。
  • 平均临床随访29±18个月。

主要发现

  • 全球队列中非抗凝组随访时平均跨瓣压差显著升高(P=0.003),抗凝组保持稳定(P=0.323)。
  • 抗凝组VHD发生率0.6%,非抗凝组3.7%(P<0.001)。
  • 倾向匹配人群中抗凝组VHD发生率0.6%,非抗凝组3.9%(P<0.001)。
  • VHD发生与全因死亡(P=0.468)、心血管死亡(P=0.539)或卒中(P=0.170)风险增加无关。

关键数值与推荐

  • VHD定义:随访时平均跨假体压差较出院时增加≥10 mm Hg。
  • 抗凝组VHD发生率0.6%,非抗凝组3.7%(P<0.001)。
  • 倾向匹配后抗凝组0.6%,非抗凝组3.9%(P<0.001)。

临床怎么用

  • TAVR术后未抗凝患者应关注跨瓣压差变化及VHD风险。
  • VHD多为亚临床,未增加死亡或卒中风险,需个体化评估抗凝获益与风险。
  • 需随机试验确定TAVR术后系统抗凝是否降低VHD发生率。

局限性

  • 原文未报告观察性设计相关的混杂控制细节。
  • 原文未报告抗凝治疗的具体适应证及用药时长。
  • 原文未报告VHD的长期临床影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the changes in transvalvular gradients and the incidence of valve haemodynamic deterioration (VHD) following transcatheter aortic valve replacement (TAVR), according to use of anticoagulation therapy. METHODS AND RESULTS: This multicentre study included 2466 patients (46% men; mean age 81±7 years) who underwent TAVR with echocardiography performed at 12-month follow-up. Anticoagulation therapy was used in 707 patients (28.7%) following TAVR (AC group). A total of 663 patients received vitamin K antagonists, and 44 patients received direct oral anticoagulants. A propensity score matching analysis was performed to adjust for intergroup (AC vs non-AC post-TAVR) differences. A total of 622 patients per group were included in the propensity-matched analysis. VHD was defined as a ≥10 mm Hg increase in the mean transprosthetic gradient at follow-up (vs hospital discharge). The mean clinical follow-up was 29±18 months. The mean transvalvular gradient significantly increased at follow-up in the non-AC group within the global cohort (P=0.003), whereas it remained stable over time in the AC group (P=0.323). The incidence of VHD was significantly lower in the AC group (0.6%) compared with the non-AC group (3.7%, P<0.001), and these significant differences remained within the propensity-matched populations (0.6% vs 3.9% in the AC and non-AC groups, respectively, P<0.001). The occurrence of VHD did not associate with an increased risk of all-cause death (P=0.468), cardiovascular death (P=0.539) or stroke (P=0.170) at follow-up. CONCLUSIONS: The lack of anticoagulation therapy post-TAVR was associated with significant increments in transvalvular gradients and a greater risk of VHD. VHD was subclinical in most cases and did not associate with major adverse clinical events. Future randomised trials are needed to determine if systematic anticoagulation therapy post-TAVR would reduce the incidence of VHD.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Del Trigo M, Muñoz-García AJ, Latib A, et al. Impact of anticoagulation therapy on valve haemodynamic deterioration following transcatheter aortic valve replacement. Heart. 2018. PMID: 29440192. doi:10.1136/heartjnl-2017-312514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。